Sign in

    Organon & Co (OGN)

    You might also like

    Organon & Co. (OGN) is a global healthcare company dedicated to improving women's health and delivering innovative health solutions. The company offers a diverse portfolio of prescription therapies and medical devices, focusing on women's health, biosimilars, and established brands. Organon operates worldwide, with a significant portion of its revenue generated outside the United States, and leverages its manufacturing facilities across multiple countries to distribute its products.

    1. Established Brands - Offers over 60 medicines across therapeutic areas such as cardiovascular, respiratory, dermatology, and non-opioid pain management, many of which have lost market exclusivity and face generic competition.
    2. Women’s Health - Focuses on contraception and fertility products, including Nexplanon (etonogestrel implant), NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), and Follistim AQ (follitropin beta injection). Also includes innovative devices like the Jada System for postpartum hemorrhage and Xaciato for bacterial vaginosis.
    3. Biosimilars - Develops and markets treatments for oncology and immunology, including products like Ontruzant (trastuzumab), Renflexis (infliximab-abda), and Hadlima (adalimumab-bwwd), with a growing presence in global markets.
    NamePositionExternal RolesShort Bio

    Kevin Ali

    Executive

    Chief Executive Officer (CEO)

    None

    CEO of Organon since its inception in 2021; previously held leadership roles at Merck, including President of Merck International and Emerging Markets.

    View Report →

    Kirke Weaver

    Executive

    EVP, General Counsel, and Corporate Secretary

    None

    General Counsel of Organon since 2021; played a key role in Organon's launch; previously held senior legal roles at Merck for 18 years.

    Matthew Walsh

    Executive

    Executive Vice President and CFO

    Board Member at Certara, Inc.

    CFO of Organon since 2021; previously EVP and CFO at Allergan and Catalent; extensive experience in financial leadership in the pharmaceutical industry.

    Carrie S. Cox

    Board

    Chairman of the Board

    Chairman at Cartesian Therapeutics and Solventum Corporation; Director at Texas Instruments Inc.

    Chairman of Organon’s Board since 2021; extensive executive experience in the pharmaceutical industry, including leadership roles at Humacyte, Schering-Plough, and Pharmacia.

    Cynthia M. Patton

    Board

    Independent Director

    General Counsel and Corporate Secretary at Tessera Therapeutics; Trustee at Vassar College; Board Member at Martin Luther King, Jr. Community Hospital and Los Angeles Music Center

    Director at Organon since 2021; legal and compliance expert with leadership experience at Verily Life Sciences and Amgen.

    Deborah Leone

    Board

    Independent Director

    Director at Goldman Sachs Bank USA, Goldman Sachs Philanthropy Fund, Ayco Charitable Foundation; Trustee at Syracuse University; Director at Corebridge Financial, Inc.

    Director at Organon since 2021; retired partner at Goldman Sachs with expertise in financial and operational leadership.

    Grace Puma

    Board

    Independent Director

    Director at Target Corporation

    Director at Organon since 2021; former EVP and COO at PepsiCo; extensive expertise in global procurement and supply chain management.

    Helene Gayle, M.D.

    Board

    Independent Director

    President of Spelman College; Director at The Coca-Cola Company and Palo Alto Networks Inc.

    Director at Organon since 2021; global health expert with leadership experience in public health and non-profit organizations; President of Spelman College.

    Rochelle Lazarus

    Board

    Independent Director

    Chairman Emeritus of Ogilvy & Mather; Director at Blackstone, Inc. and Rockefeller Capital Management

    Director at Organon since 2021; extensive experience in advertising and marketing; serves on multiple boards and charitable organizations.

    Shalini Sharp

    Board

    Independent Director

    Director at Neurocrine Biosciences, Inc.

    Director at Organon since 2021; financial expert with extensive experience in the biopharmaceutical industry, including CFO roles at Ultragenyx and Agenus.

    1. With the $180 million operating expense for Dermavant in 2025 primarily focused on launching VTAMA in atopic dermatitis , how confident are you in achieving the projected sales of at least $150 million , and what contingencies are in place if the launch underperforms?

    2. Given that VTAMA's performance in the psoriasis market was limited, and you have high expectations for its potential in atopic dermatitis , what specific strategies will you employ to overcome the challenges faced in psoriasis and ensure success in this larger but competitive market?

    3. You mentioned that the Dermavant acquisition will be dilutive to profitability in 2025 by about 0.5 percentage points of EBITDA margin , how do you plan to offset this dilution, and what measures are you taking to ensure it becomes accretive in 2026 and beyond?

    4. The Fertility business is facing a softer outlook for the year, tempering down from a 9% volume growth rate to approximately 7% , could you elaborate on the factors contributing to this slowdown and how you plan to achieve the projected strong rebound in 2025?

    5. With increasing competitive pressures and pricing headwinds in certain mature products such as NuvaRing, DULERA, and RENFLEXIS , how do you intend to mitigate these challenges to maintain your gross margin and overall profitability?

    CustomerRelationshipSegmentDetails

    McKesson

    Major drug wholesaler

    All

    12% of total gross A/R as of 12/31/2024

    Cardinal Health

    Major drug wholesaler

    All

    7% of total gross A/R as of 12/31/2024

    Cencora, Inc.

    Major drug wholesaler

    All

    6% of total gross A/R as of 12/31/2024

    Notable M&A activity and strategic investments in the past 3 years.

    CompanyYearDetails

    Dermavant Sciences Ltd.

    2024

    Completed acquisition where Organon executed a merger via its subsidiary with Dermavant, with total potential consideration of up to $1.2 billion (including an upfront payment of $175 million, milestone and commercial payments) to bolster its dermatology portfolio with VTAMA® (tapinarof) cream, subject to FDA approval and regulatory conditions.

    Claria Medical, Inc.

    2023

    Planned acquisition/investment via a strategic investment, involving an $8 million upfront payment with an option to acquire the company for an additional $47 million based on milestones, intended to develop an investigational device for minimally invasive laparoscopic hysterectomy.

    Bayer AG (Product rights for Marvelon™ and Mercilon™)

    2022

    Completed asset acquisition of the product rights and related inventory for Marvelon™ and Mercilon™, executed in stages across 2022 with payments of $30 million (plus $35 million subsequently) for China and $30 million for Vietnam, thereby expanding Organon’s prescription contraceptive portfolio in key Asian markets.

    No recent press releases or 8-K filings found for OGN.